Awards Registry

Fpia For Saquinavir And Ritonavir Hiv Inhibitors
Profile last edited on:

Program
SBIR
Agency
NIH | NIAID
Total Award Amount
$153,055
Award Phase
1
Principal Investigator
Charles A Harrington
Activity Indicator

Company Information

Abacus Diagnostics Systems Inc

4401 Fredrich Lane Suite 100
Austin, TX 78744
   (512) 442-8841
   N/A
   N/A
Multiple Locations:   
Congressional District:   35
County:   Travis

Phase I

Phase I year
2000
Phase I Amount
$153,055
Currently, efficacious treatment of human beings infected with HIV is best accomplished by use of a mixture, or cocktail, of different drugs that act as inhibitors of key enzymes that control different stages in viral development, assembly and/or propagation. Integral drugs in that cocktail are the HIV Specific Protease inhibitors saquinavir and ritonavir. Immunoassay analysis of saquinavir and ritonavir would provide an analytically suitable, clinically useful therapeutic monitoring methodology. Fluorescence polarization immunoassays (FPIA) represent a suitable method for these types of measurements that has proven especially useful and cost effective in monitoring anti infectives. Two milestones are extant in this proposal: (1) Preparation of the poly/monoclonal immunoreagents and fluorescent tracers used in FPIA and (2) Demonstration of the feasibility and suitability of those reagents in an automated assay paradigm. PROPOSED COMMERCIAL APPLICATION: Measurement of HIV Protease Inhibitors will become a standard of treatment in the application of these drugs in my. Providing a cost effective and efficient analytical methodology, such as FPIA. Provision of that measurement will greatly enhance the efficacious use of these drugs.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Antiaids Agent, Antibody, Antiviral Agent, Fluorescence Polarization, Immunologic Assay /Test, Immunologic Preparation, Ritonavir, Saquinavir Drug Screening /Evaluation Goat, Laboratory Rabbit

Phase II

Phase II year
---
Phase II Amount
---